01779
114.9001.29%
$WUXI BIO(02269.HK) has barely moved. $LONGBIO-B(01779.HK) started to dip slightly less than a week after listing. $Recursion Pharmaceuticals(RXRX.US) fell three percentage points. The recent script for innovative drug stocks has been "BD-driven big orders create a pulse," while on days without concrete deals, they all lie flat collectively.
For a newly listed allergy-sector stock like $LONGBIO-B(01779.HK), why did its first-day hype fade so quickly? Is it the routine withdrawal of IPO subscription funds, or is the market becoming picky again about biotechs without commercialized products? It's more likely the former—the scarcity of the IgE target remains, but we need to wait for the data to speak.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.